Literature DB >> 31638492

Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes.

Feng Shi1, Ming Wu1, Shan-Shan Lian1, Zhi-Qiang Mo1, Qing Gou1, Rong-De Xu1, Hui-Lan Li1, Zhi-Mei Huang1, Pei-Hong Wu1, Xiao-Ming Chen1.   

Abstract

Background Transarterial chemoembolization (TACE) is an effective downstaging procedure for hepatocellular carcinoma (HCC). However, knowledge of the effectiveness of radiofrequency ablation (RFA) after downstaging of HCC is currently lacking. Purpose To evaluate the clinical outcomes of RFA after downstaging of HCC by using TACE. Materials and Methods This retrospective study investigated a cohort of patients who underwent RFA with curative intent after downstaging with TACE to meet Milan criteria (one lesion up to 5 cm or no more than three lesions ≤3 cm without vascular invasion or extrahepatic metastasis) from January 2012 to July 2017. A control group of patients initially meeting the Milan criteria also underwent RFA as first-line treatment in the same period. Overall survival (OS), disease-free survival (DFS), and major complication rates were compared by using the log-rank test. To reduce potential bias, a propensity score analysis was also performed. Results There were 72 patients (median age, 56.5 years; range, 30-78 years; 67 men) in the downstaging group and 357 patients meeting the Milan criteria (median age, 58.0 years; range, 25-87 years; 313 men) included in this study. After propensity score matching, the 1-, 3-, and 5-year OS rates were 99%, 80%, and 66%, respectively, for the patients in the downstaging group and 94%, 84%, and 69%, respectively, for the patients in the Milan criteria group. The 1-, 3-, and 5-year DFS rate were 73%, 34%, and 24% for the downstaging group and 74%, 43%, and 37% for the Milan criteria group. There were no differences in the OS, DFS, or major complication rates between the two groups (P = .74, P = .39, P = .73, respectively). Conclusion The long-term patient survival and major complication rates of radiofrequency ablation following transarterial chemoembolization downstaging for hepatocellular carcinoma were similar to that of patients initially meeting the Milan criteria. © RSNA, 2019 See also the editorial by vanSonnenberg and Mueller in this issue.

Entities:  

Mesh:

Year:  2019        PMID: 31638492     DOI: 10.1148/radiol.2019181991

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

Review 1.  Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO).

Authors:  Jian Lu; Ming Zhao; Yasuaki Arai; Bin-Yan Zhong; Hai-Dong Zhu; Xiao-Long Qi; Thierry de Baere; Uei Pua; Hyun Ki Yoon; David C Madoff; Gao-Jun Teng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-10       Impact factor: 7.293

2.  Recurrence Beyond the Milan Criteria of HBV-Related Single Hepatocellular Carcinoma of 2-3 cm: Comparison of Resection and Ablation.

Authors:  Shuanggang Chen; Weimei Ma; Lujun Shen; Ying Wu; Han Qi; Fei Cao; Tao Huang; Weijun Fan
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

3.  Intelligent Algorithm-Based Ultrasound Images in Evaluation of Therapeutic Effects of Radiofrequency Ablation for Liver Tumor and Analysis on Risk Factors of Postoperative Infection.

Authors:  Lou Kexin; Chen Ning; Li Zhihong; Xiao Shuo; Wu Rong
Journal:  Contrast Media Mol Imaging       Date:  2022-09-30       Impact factor: 3.009

4.  Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations.

Authors:  Qi-Feng Chen; Wang Li; Simon Chun-Ho Yu; Yi-Hong Chou; Hyunchul Rhim; Xiaoming Yang; Lujun Shen; Annan Dong; Tao Huang; Jinhua Huang; Fujun Zhang; Weijun Fan; Ming Zhao; Yangkui Gu; Zhimei Huang; Mengxuan Zuo; Bo Zhai; Yueyong Xiao; Ming Kuang; Jiaping Li; Jianjun Han; Wei Song; Jie Ma; Peihong Wu
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

5.  Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study.

Authors:  Yi Yang; Yanzhao Zhou; Xinyuan Zhang; Yujing Xin; Yi Chen; Qingsheng Fan; Xiao Li; Xi Wei; Qiang Li; Xiang Zhou; Jinxue Zhou
Journal:  J Hepatocell Carcinoma       Date:  2021-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.